Cellectar Biosciences Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters11-15 21:54

* Cellectar Biosciences Inc is expected to show no change in quarterly revenue when it reports results on November 18 for the period ending September 30 2024

*

* LSEG's mean analyst estimate for Cellectar Biosciences Inc is for a loss of 37 cents per share.

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Cellectar Biosciences Inc is $13.50, above its last closing price of $2.01.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.31 -0.34 -0.03 Beat 91.3

Mar. 31 2024 -0.56 -0.56 -0.74 Missed -31.4

Dec. 31 2023 -0.78 -0.57 -0.61 Missed -7

Sep. 30 2023 -0.59 -0.52 -0.83 Missed -58.1

Jun. -0.66 -0.64 -0.73 Missed -14.7

30 2023

Mar. 31 2023 -0.86 -0.87 -0.76 Beat 12.4

Dec. 31 2022 -1.07 -0.55 Beat 48.8

Sep. 30 2022 -1.21 -1.21 -1.28 Missed -5.5

This summary was machine generated November 15 at 13:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483691379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483691379","market":"us","top_or_hot":-1,"title":"Cellectar Biosciences Inc    expected to post a loss of 37 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Cellectar Biosciences Inc     is expected to show no change in quarterly revenue when it reports  results on November 18 for the period ending September 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Cellectar Biosciences Inc is for a loss of 37 cents per share. </p><p>   * The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Cellectar Biosciences Inc is $13.50, above its last closing price of $2.01. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.31       -0.34      -0.03     Beat    91.3</p><p>Mar. 31 2024  -0.56       -0.56      -0.74     Missed  -31.4</p><p>Dec. 31 2023  -0.78       -0.57      -0.61     Missed  -7</p><p>Sep. 30 2023  -0.59       -0.52      -0.83     Missed  -58.1</p><p>Jun.        -0.66       -0.64      -0.73     Missed  -14.7</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.86       -0.87      -0.76     Beat    12.4</p><p>Dec. 31 2022              -1.07      -0.55     Beat    48.8</p><p>Sep. 30 2022  -1.21       -1.21      -1.28     Missed  -5.5</p><p>This summary was machine generated November 15 at 13:54 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectar Biosciences Inc    expected to post a loss of 37 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectar Biosciences Inc    expected to post a loss of 37 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Cellectar Biosciences Inc     is expected to show no change in quarterly revenue when it reports  results on November 18 for the period ending September 30 2024   *    * LSEG's mean analyst ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLRB","symbol_name":"Cellectar Biosciences Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2483691379","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483691379","pubTimestamp":1731678846,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Cellectar Biosciences Inc     is expected to show no change in quarterly revenue when it reports  results on November 18 for the period ending September 30 2024   *    * LSEG's mean analyst estimate","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CLRB":"Cellectar Biosciences Inc."},"translate_title":"Cellectar Biosciences Inc预计每股亏损37美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLRB":1},"content_text":"* Cellectar Biosciences Inc     is expected to show no change in quarterly revenue when it reports  results on November 18 for the period ending September 30 2024   *    * LSEG's mean analyst estimate for Cellectar Biosciences Inc is for a loss of 37 cents per share.    * The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Cellectar Biosciences Inc is $13.50, above its last closing price of $2.01. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.31       -0.34      -0.03     Beat    91.3Mar. 31 2024  -0.56       -0.56      -0.74     Missed  -31.4Dec. 31 2023  -0.78       -0.57      -0.61     Missed  -7Sep. 30 2023  -0.59       -0.52      -0.83     Missed  -58.1Jun.        -0.66       -0.64      -0.73     Missed  -14.730 2023                                                Mar. 31 2023  -0.86       -0.87      -0.76     Beat    12.4Dec. 31 2022              -1.07      -0.55     Beat    48.8Sep. 30 2022  -1.21       -1.21      -1.28     Missed  -5.5This summary was machine generated November 15 at 13:54 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483691379"}